Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks

No authors listed

No authors listed. Harv Health Lett. 2005 Mar.

. 2005 Mar;30(5):1-3.

No abstract available

Similar articles

The COX-2 inhibitors--an update.
Furberg CD. Furberg CD. Am Heart J. 2006 Aug;152(2):197-9. doi: 10.1016/j.ahj.2006.05.022. Am Heart J. 2006. PMID: 16875896 No abstract available.
COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV, Barnett EM, Randels CL. Bobadilla RV, et al. Adv Nurse Pract. 2005 Nov;13(11):48-50. Adv Nurse Pract. 2005. PMID: 16295003 Review. No abstract available.
Coxibs and cardiovascular disease.
Fitzgerald GA. Fitzgerald GA. N Engl J Med. 2004 Oct 21;351(17):1709-11. doi: 10.1056/NEJMp048288. Epub 2004 Oct 6. N Engl J Med. 2004. PMID: 15470192 No abstract available.
[Cardiovascular events: a class effect by COX-2 inhibitors].
Araujo LF, Soeiro Ade M, Fernandes Jde L, Serrano Júnior CV. Araujo LF, et al. Arq Bras Cardiol. 2005 Sep;85(3):222-9. doi: 10.1590/s0066-782x2005001600016. Epub 2005 Sep 29. Arq Bras Cardiol. 2005. PMID: 16200274 Review. Portuguese. No abstract available.
COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM. Drazen JM. N Engl J Med. 2005 Mar 17;352(11):1131-2. doi: 10.1056/NEJMe058038. Epub 2005 Feb 15. N Engl J Med. 2005. PMID: 15713947 No abstract available.